“In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders and sub-regulatory guidance that may impact pricing for pharmaceutical products. These initiatives include, among others… implementation of the inflation Reduction Act of 2022 (Inflation Reduction Act), including provisions that generally require manufacturers of Medicare Part B and Part D drugs to pay inflation rebates to the Medicare program if pricing metrics associated with their products increase faster than the rate of inflation;”
All entries for: Cardiology
March 5, 2026
Lexicon Pharmaceuticals
Negative Outlook
The Woodlands, TX
51-200 employees
Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time.
Disease Area: Cardiology, Endocrinology, Metabolic Diseases, Neurological Diseases
Drug Type: Small Molecule
March 5, 2026
Liquidia Corp
Neutral Outlook
Morrisville, NC
51-200 employees
For these and other reasons, it is currently unclear how the IRA will be effectuated and the impact of the IRA on the pharmaceutical industry and on generic drug pricing cannot yet be fully determined
Disease Area: Cardiology, Rare Diseases, Respiratory Diseases
Drug Type: Small Molecule
March 3, 2026
CalciMedica, Inc.
Negative Outlook
La Jolla, California
1-50 employees
For example, the Inflation Reduction Act (“IRA”) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Cardiology, Gastrointestinal, Immune Diseases, Respiratory Diseases
Drug Type: Small Molecule
February 27, 2026
Ligand Pharmaceuticals Inc
Neutral Outlook
Jupiter. FL
1-50 employees
Most significantly, on August 16, 2022, the former President Biden signed the Inflation Reduction Act of 2022 (“IRA”) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.
Disease Area: Cardiology, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
February 27, 2026
Amneal Pharmaceuticals Inc
Negative Outlook
Bridgewater, NJ
5,001-10,000 employees
The drug pricing reforms in the IRA have impacted, and may impact in the future, the prices of certain of our products.
Disease Area: Cardiology, Dermatology, Endocrinology, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 26, 2026
BioMarin Pharmaceutical Inc.
Neutral Outlook
San Rafael, CA
1000-5000 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic, Small Molecule
February 26, 2026
Rocket Pharmaceuticals
Neutral Outlook
Cranbury, NJ
201-500 employees
Implementation of the Inflation Reduction Act has occurred, but the results of its impact on the market for drugs, including our products, remains uncertain.
Disease Area: Cardiology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Biologic
February 26, 2026
Ionis Pharmaceutical
Neutral Outlook
Carlsbad, CA
1,001-5,000 employees
In addition, the Inflation Reduction Act of 2022, or the IRA, includes key actions aimed at reducing the costs of prescription drugs and allows HHS to negotiate the price of certain single-source drugs covered under Medicare and establish a price cap on such drugs.
Disease Area: Antiviral, Cardiology, Chronic Disease, Hematology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic